2025-05-27
A SENOVA fará uma exposição na
Medicamento de Emagrecimento Saxenda da Novo é Considerado Seguro e Efetivo para Reduzir o IMC em Crianças
Tempo: 2024-09-18
Fonte: PharmaCompass
Autor: SENOVA—Lucas
Novo Nordisk's older weight loss drug Saxenda (liraglutide) has shown promising results in safely treating obesity in children aged 6 to 12 years. This marks a significant development in the field of pediatric obesity treatment, as there are currently no drugs approved for use in children under 12. This 56-week trial involved 92 children, and the results showed that the BMI of children receiving daily Saxenda injections decreased by 7.4% compared to the placebo group. Given the rising rates of childhood obesity, these results are particularly noteworthy. However, experts warn about the long-term effects of this treatment on child development.
